Abstract Poster Wall

Abstract 6

Durable response to immunotherapy-based regimens for IMDC favorable risk patients with metastatic clear cell renal cell carcinoma: a pooled analysis of four published randomized control phase 3 trial

Albert Jang MD

Abstract 9

Delving into molecular underpinnings of sarcomatoid/rhabdoid dedifferentioation in renal cancers using spatial profiling

Yasser Riazalhosseini PhD

Abstract 18

Unraveling the Impact of Tumor Microenvironment on Immunotherapy Response/Resistance in Human Sarcomatoid Clear Cell Renal Cell Carcinoma: Insights from a Novel Mouse Model

Hui Jiang PhD

Abstract 23

Pre-surgical visceral adipose tissue may be a novel pre-surgical risk factor for acute kidney injury among clear cell renal cell cancer patients undergoing radical nephrectomy

Alejandro Sanchez MD

Abstract 26

Applying single cell RNA sequencing of sarcomatoid renal cell carcinoma for the development of a novel transcriptomic biomarker to predict immunotherapy response

Nicholas Salgia BSc

Abstract 30

Synergistic systematic analysis with fully human tissue models and in silico modeling of “copycats” reveals mechanisms of T cell suppression in clear cell renal cell carcinoma

Xin-Wen Zhang MD

Abstract 36

Real-world treatment patterns and clinical outcomes of metastatic renal cell carcinoma patients post
immune-oncology (IO) and Vascular Endothelial Growth Factor (VEGF) receptor targeted therapies

Neil Shah MD

Abstract 40

Preclinical evaluation of a novel dendritic cell vaccine for kidney cancer

David Gau PhD

Abstract 46

Radiological tumor burden is an independent risk factor for survival in patients with metastatic clear cell renal cell carcinoma (mccRCC) treated with first line immunotherapy (IO)-based regimens

Rashad Nawfal MD

Abstract 49

Inhibition of AXL along with c-Met potentially halts resistance development in renal cell carcinoma

Marc Machaalani MD

Abstract 51

Epigenetic regulation of ribosomal RNA transcription and processing by the tumor suppressor SETD2

Frank Mason, PhD

Abstract 54

MicroRNA Signatures in Clear Cell Renal Cell Carcinoma: Exploring Potential Implications for Prognosis

Minghui Zhang MHS

Abstract 56

Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Relationship Confirms Best-in-class Potential of Casdatifan (AB521), a Small Molecule Inhibitor of HIF-2α Being Developed in Renal Cancer

Mohammad Ghasemi PhD

Abstract 59

Risk Factors of Immune Related Adverse Events in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors

Razane El Hajj Chehade MD

Abstract 62

Prognostic biomarker development using deep learning and spatial proteomics in papillary renal cell carcinoma

Jared Brewer PhD

Abstract 68

Use of artificial intelligence to derive International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) elements from unstructured medical records

Salvador Jaime-Casas MD

Abstract 70

Circulating leptin and immune-related transcriptomic patterns in clear cell renal cell carcinoma

Lina Posada Calderon MD

Abstract 72

Impact of microbiome modulation on serum cytokine profile in a randomized, phase I trial of cabozantinib/nivolumab (cabo/nivo) with or without CBM588 in pts with metastatic renal cell carcinoma (mRCC)

Yu Jun Li

Abstract 5

A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREGTM) in Patients with Advanced or Metastatic Renal Cell Carcinoma, NCT06234605

Rana R McKay MD

Abstract 29

Pilot study of an implantable microdevice for in vivo evaluation of drug response in renal cell carcinoma (NCT05700461)

Wenxin Xu MD

Abstract 75

WIRE: Window of Opportunity Clinical Trials Platform for Evaluation of Novel Treatments Strategies in Renal Cell Cancer

Grant Stewart MD, PhD

Abstract 15

Molecular Residual Disease (MRD) Guided Adjuvant Therapy in Rental Cell Carcinoma (RCC) -MRD Gate RCC

Arnab Basu MD, MPH

Abstract 31

Multiplexed Quantification of Urinary Biomarkers for Non-invasive Classification of Imaged Kidney Tumors

Jeremiah Morrissey PhD

Abstract 65

Phase II Study of Bevacizumab, Erlotinib and Atezolizumab in Patients with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer

Gabriela Bravo Montenero MD

Abstract 76

SWOG S2200 (PAPMET2): A phase II randomized trial of cabozantinib (cabo) with or without atezolizumab (atezo) in patients with advanced papillary renal cell carcinoma (PRCC)

Benjamin Maughan MD, PharmD